Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Capital Expenditures (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Capital Expenditures for 13 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures changed N/A to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$470.3 million through Dec 2025, down 106.43% year-over-year, with the annual reading at -$470.3 million for FY2025, 106.43% down from the prior year.
  • Capital Expenditures hit $8.4 million in Q4 2025 for Coherus Oncology, up from -$483.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.4 million in Q4 2025 to a low of -$483.4 million in Q2 2025.
  • Historically, Capital Expenditures has averaged -$43.4 million across 5 years, with a median of $206500.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: surged 324.14% in 2022 and later crashed 123667.76% in 2024.
  • Year by year, Capital Expenditures stood at $468000.0 in 2021, then plummeted by 81.41% to $87000.0 in 2022, then tumbled by 60.92% to $34000.0 in 2023, then plummeted by 117747.06% to -$40.0 million in 2024, then skyrocketed by 120.94% to $8.4 million in 2025.
  • Business Quant data shows Capital Expenditures for CHRS at $8.4 million in Q4 2025, -$483.4 million in Q2 2025, and $4.7 million in Q1 2025.